Phase II study of docetaxel alternating with cisplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer

Mattson, Karin; Vansteenkiste, Johan; Stupp, Roger; Bargetzi, Mario; Saarinen, Antti; Jekunen, Antti; Fillet, Georges; Teixeira, Maria; Gatzemeier, Ulrich; Olivares, Robert; Soussan-Lazard, Karen; Berille, Jocelyne

doi:10.1097/00001813-200001000-00002

Article (Scientific journals)

Phase II study of docetaxel alternating with cisplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer

Mattson, Karin; Vansteenkiste, Johan; Stupp, Roger et al.

2000 • In Anti-Cancer Drugs, 11, p. 7-13

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/12964

DOI
10.1097/00001813-200001000-00002

PubMed
10757557

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

150.pdf

Publisher postprint (580.18 kB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

alternating schedule; cisplatin; docetaxel; firstline chemotherapy; non-small lung cancer

Disciplines :

Hematology

Author, co-author :

Mattson, Karin

Vansteenkiste, Johan

Stupp, Roger

Bargetzi, Mario

Saarinen, Antti

Jekunen, Antti

Fillet, Georges ; Université de Liège - ULiège > Département des sciences cliniques > Hématologie - Oncologie médicale

Teixeira, Maria

Gatzemeier, Ulrich

Olivares, Robert

Soussan-Lazard, Karen

Berille, Jocelyne

Language :

English

Title :

Phase II study of docetaxel alternating with cisplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer

Publication date :

2000

Journal title :

Anti-Cancer Drugs

ISSN :

0959-4973

eISSN :

1473-5741

Publisher :

Lippincott Williams & Wilkins, London, United Kingdom

Volume :

Pages :

7-13

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 20 May 2009

Statistics

Number of views

61 (5 by ULiège)

Number of downloads

409 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

1. Landis SH, Murray T, Bolden S, et al. Cancer statistics. Cancer J Clin Cancer Res 1998; 48: 6-29.
2. Bunn PA Jr, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 1998; 5: 1087-100.
3. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995; 311: 899-909.
4. Ratain MJ Pharmacology of cancer chemotherapy. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. Philadelphia, PA: Lippincott-Raven 1997: 375-512.
5. Donnadieu N, Paesmans M, Sculier JP. Chemotherapy of non-small cell lung cancer according to disease extent: a meta-analysis of the literature. Rev Mal Resp 1991; 8: 197-204.
6. Hill BT, Whelan RDH, Shetland SA, et al. Differential cytotoxic effects of Taxotere® in a range of mammalian tumour cell lines in vitro. Ann Oncol 1992; 3 (suppl 1): 247.
7. Ringel L, Horwitz SB. Studies with RP56976 (Taxotere®): a semi-synthetic analog of Taxol®. J Natl Cancer Inst 1991; 83: 288-91.
8. Gueritte-Voegelein F, Guenard D, Lavelle F, et al. Relationship between the structure of Taxol® analogues and their anti-mitotic activity. J Med Chem 1991; 4: 992-8.
9. Rigas JR. Single agent docetaxel in previously untreated non-small cell lung cancer. Oncology 1997; 11 (suppl 7): 17-21.
10. Braakhuis BJM, Hill BT, Dietel M. In vitro antiproliferative activity of docetaxel (Taxotere®), paclitaxel (Taxol®) and cisplatin against human tumour and normal bone marrow cells. Anticancer Res 1994; 14: 205-8.
11. Casazza AM, Rose WC, Fairchild CR, et al. Preclinical biological profile of Taxol® and Taxotere®. Proc Am Ass Cancer Res 1993; 4: 380 (abstr 2267).
12. Bissery MC, Vrignaud P, Bayssas M. In vivo evaluation of Taxotere® (RP56976, NSC628503) in combination with cisplatinum, doxorubicin or vincristine. Proc Am Ass Cancer Res 1992; 33: 443 (abstr 2645).
13. Pronk LC, Schellens JH, Planting AS, et al. Phase I and pharmacologie study of docetaxel and cisplatin in patients with advanced solid tumor. J Clin Oncol 1997; 15: 1071-9.
14. Millward MJ, Zalcberg J, Bishop JF, et al. Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small cell lung cancer. J Clin Oncol 1997; 15: 750-8.
15. Le Chevalier T, Monnier A, Douillard J-Y, et al. Docetaxel plus cisplatin: an active and well-tolerated combination in patients with advanced non-small cell lung cancer. Eur J Cancer 1998; 34: 2032-6.
16. Belani CP, Bonomi P, Dobbs T, et al. Docetaxel and cisplatin combination in patients with non-small cell lung cancer (NSCLC): a multicenter phase II trial. Lung Cancer 1997; 18 (suppl 1): 12 (abstr 37).
17. Gralla RJ, Cole JT, Robertson CN, et al. Docetaxel plus cisplatin: an active combination regimen in non-small cell lung cancer. Oncology 1997; 11 (suppl 7): 27-30.
18. Mattson K, Saarinen A, Jekunen A. Combination treatment with docetaxel (Taxotere®) and platinum compounds for non-small cell lung cancer. Semin Oncol 1997; 24 (suppl 14): 5-8.
19. Zalcberg J, Millward M, Bishop J, et al. Phase II study of docetaxel and cisplatin in advanced non-small cell lung cancer. J Clin Oncol 1998; 16: 1948-53.
20. Miller AB, Hoogstraten B, Staaquet M, et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
21. Fleming TO. One sample multiple testing procedure for phase II clinical trials. Biometrics 1982; 38: 143-51.
22. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
23. Hryniuk WM. Average relative dose intensity and the impact on design of clinical trials. Semin Oncol 1987; 14: 65-74.
24. Le Chevalier T, Bérille J, Zalcberg J, et al. Overview of docetaxel (Taxotere®)/cisplatin combination in non-small cell lung cancer. Semin Oncol 1999; 3 (suppl 11): 13-8.
25. Viallet J, Laberge F, Martins H, et al. Docetaxel alternating with cisplatin and vinorelbine: early evidence of additive activity in a phase II trial of non-small cell lung cancer. Proc Am Soc Clin Oncol 1996; 15: 375 (abstr 1115).